Post-marketing Surveillance of Spesolimab I.V. Infusion in improvement of Generalized Pustular Psoriasis (GPP) with acute symptoms in Japan (PMS for GPP with acute symptoms)

25/11/2022
02/09/2024
EU PAS number:
EUPAS49953
Study
Planned
Documents
Study protocol
Study results
Study report
Other information